Kovack Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.48M | Sell |
17,794
-7,627
| -30% | -$1.07M | 0.13% | 146 |
|
|
2025
Q4 | $3.12M | Buy |
25,421
+21,643
| +573% | +$2.63M | 0.15% | 126 |
|
|
2025
Q3 | $419K | Sell |
3,778
-8
| -0.2% | -$909 | 0.04% | 376 |
|
|
2025
Q2 | $420K | Sell |
3,786
-329
| -8% | -$35K | 0.04% | 378 |
|
|
2025
Q1 | $461K | Sell |
4,115
-3,680
| -47% | -$380K | 0.05% | 320 |
|
|
2024
Q4 | $720K | Sell |
7,795
-1,318
| -14% | -$119K | 0.07% | 230 |
|
|
2024
Q3 | $764K | Sell |
9,113
-1,216
| -12% | -$92.8K | 0.08% | 210 |
|
|
2024
Q2 | $709K | Sell |
10,329
-5
| -0% | -$334 | 0.08% | 233 |
|
|
2024
Q1 | $757K | Sell |
10,334
-161
| -2% | -$12.4K | 0.09% | 184 |
|
|
2023
Q4 | $850K | Buy |
10,495
+685
| +7% | +$53.3K | 0.1% | 194 |
|
|
2023
Q3 | $735K | Sell |
9,810
-547
| -5% | -$42.1K | 0.1% | 186 |
|
|
2023
Q2 | $798K | Sell |
10,357
-420
| -4% | -$33.5K | 0.1% | 193 |
|
|
2023
Q1 | $894K | Buy |
10,777
+35
| +0.3% | +$2.9K | 0.12% | 173 |
|
|
2022
Q4 | $922K | Sell |
10,742
-510
| -5% | -$40.4K | 0.13% | 154 |
|
|
2022
Q3 | $694K | Buy |
11,252
+26
| +0.2% | +$1.64K | 0.1% | 212 |
|
|
2022
Q2 | $694K | Buy |
11,226
+1,022
| +10% | +$63.3K | 0.09% | 239 |
|
|
2022
Q1 | $606K | Sell |
10,204
-1,607
| -14% | -$103K | 0.06% | 340 |
|
|
2021
Q4 | $858K | Sell |
11,811
-1,483
| -11% | -$102K | 0.08% | 262 |
|
|
2021
Q3 | $929K | Buy |
13,294
+6,667
| +101% | +$468K | 0.1% | 231 |
|
|
2021
Q2 | $456K | Sell |
6,627
-85
| -1% | -$5.68K | 0.05% | 381 |
|
|
2021
Q1 | $434K | Sell |
6,712
-7,480
| -53% | -$482K | 0.06% | 350 |
|
|
2020
Q4 | $827K | Buy |
14,192
+395
| +3% | +$23.8K | 0.12% | 190 |
|
|
2020
Q3 | $872K | Buy |
13,797
+272
| +2% | +$18.9K | 0.16% | 154 |
|
|
2020
Q2 | $1.04M | Sell |
13,525
-2,356
| -15% | -$181K | 0.2% | 125 |
|
|
2020
Q1 | $1.19M | Buy |
15,881
+11,915
| +300% | +$823K | 0.27% | 92 |
|
|
2019
Q4 | $258K | Sell |
3,966
-1,494
| -27% | -$97.3K | 0.05% | 393 |
|
|
2019
Q3 | $346K | Buy |
5,460
+236
| +5% | +$15.4K | 0.07% | 301 |
|
|
2019
Q2 | $353K | Sell |
5,224
-154
| -3% | -$10.1K | 0.08% | 267 |
|
|
2019
Q1 | $350K | Sell |
5,378
-802
| -13% | -$53.3K | 0.09% | 257 |
|
|
2018
Q4 | $387K | Sell |
6,180
-4,572
| -43% | -$320K | 0.11% | 212 |
|
|
2018
Q3 | $830K | Buy |
10,752
+1,377
| +15% | +$104K | 0.21% | 118 |
|
|
2018
Q2 | $664K | Sell |
9,375
-8,086
| -46% | -$571K | 0.19% | 142 |
|
|
2018
Q1 | $1.32M | Sell |
17,461
-10,156
| -37% | -$807K | 0.33% | 67 |
|
|
2017
Q4 | $1.98M | Buy |
27,617
+9,839
| +55% | +$747K | 0.5% | 36 |
|
|
2017
Q3 | $1.44M | Sell |
17,778
-2,355
| -12% | -$180K | 0.48% | 44 |
|
|
2017
Q2 | $1.43M | Buy |
20,133
+5,516
| +38% | +$367K | 0.45% | 45 |
|
|
2017
Q1 | $993K | Sell |
14,617
-4,142
| -22% | -$291K | 0.39% | 53 |
|
|
2016
Q4 | $1.34M | Buy |
+18,759
| New | +$1.39M | 0.64% | 32 |
|
|
2016
Q3 | – | Sell |
-7,847
| Closed | -$655K | – | 283 |
|
|
2016
Q2 | $655K | Sell |
7,847
-2,252
| -22% | -$200K | 0.35% | 68 |
|
|
2016
Q1 | $928K | Sell |
10,099
-2,799
| -22% | -$252K | 0.58% | 38 |
|
|
2015
Q4 | $1.3M | Buy |
12,898
+2,088
| +19% | +$217K | 0.86% | 26 |
|
|
2015
Q3 | $1.06M | Sell |
10,810
-700
| -6% | -$77.7K | 0.74% | 31 |
|
|
2015
Q2 | $1.35M | Buy |
11,510
+3,768
| +49% | +$412K | 0.95% | 23 |
|
|
2015
Q1 | $760K | Sell |
7,742
-262
| -3% | -$26.6K | 0.64% | 37 |
|
|
2014
Q4 | $754K | Buy |
8,004
+5,443
| +213% | +$563K | 0.78% | 28 |
|
|
2014
Q3 | $273K | Buy |
+2,561
| New | +$251K | 0.4% | 58 |
|
Other funds holding GILD
VCM
VPM
Kovack Advisors's GILD Position: Q1 2026 in Review
Kovack Advisors reduced its Gilead Sciences (GILD) stake by 30% in Q1 2026, selling an estimated $1.07M and leaving 17,794 shares worth $2.48M. The position accounts for 0.13% of the portfolio, ranked #146.
Kovack Advisors first reported a position in GILD in Q3 2014 and has held it in 46 quarters since. The position peaked at $3.12M in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Kovack Advisors held 17,794 shares of Gilead Sciences worth $2.48M as of Q1 2026.
- Kovack Advisors sold 7,627 Gilead Sciences shares in Q1 2026, an estimated $1.07M.
- Gilead Sciences made up 0.13% of Kovack Advisors's portfolio in Q1 2026, its #146 holding.
- Kovack Advisors first reported a position in Gilead Sciences in Q3 2014 and has held it in 46 quarters since.
- Kovack Advisors's Gilead Sciences position peaked at $3.12M in Q4 2025.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.